The first domestic herpes zoster vaccine will arrive! Bacitracin announces the approval of its marketing authorization application
Jan. 31 (Xinhua) — Bac Bio (688276.SH) announced that it recently received the Drug Registration Certificate for the live attenuated herpes zoster vaccine from the State Drug Administration. Currently, there are only two imported herpes zoster vaccines approved for the market, which means that Bacopac’s herpes zoster vaccine may become the first domestic product.
According to Bacera, the live attenuated herpes zoster vaccine has to obtain the certificate of registration of the product and complete the procedures of access to various places after obtaining the certificate of registration of the product, so there is a certain uncertainty in the time of market sales. It is reported that the vaccine is suitable for adults aged 40 years and above.
At present, shingles is mainly treated with antiviral and symptomatic therapy, and there is no specific drug yet. The only two herpes zoster vaccines approved in the world are Merck Sharp & Dohme’s Zostavax and GlaxoSmithKline’s Shingrix, which are live attenuated vaccines and recombinant subunit vaccines, respectively.
The herpes zoster vaccine is also known as the “HPV vaccine for the elderly” because it is as important to the elderly as the HPV vaccine is to women.
According to the Red Star Capital Bureau incomplete statistics, there are also domestic herpes zoster vaccines in research, including Watson Biological (300142.SZ), Shanghai Institute of Biological Products, Praying Health Biology, Zhong Hui Yuan Tong Biology, and Green Bamboo Biology, a subsidiary of Saisheng Pharmaceutical (300485.SZ).
In addition, on January 31, Bacitracin also announced that it intends to plan an overseas issuance of global depositary receipts and listing on the Swiss Stock Exchange in order to expand Bacitracin’s international financing channels and to enhance the company’s international brand and image, among other reasons.
Average Rating